Euroopan unioni - suomi - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - rintojen kasvaimet - endokriinihoito - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.